8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 12, 2026·SEC
OnKure Therapeutics, Inc.(OKUR)Earnings, Financials & Key Ratios
OKUR•NASDAQ
$4.60
Price updated Jul 6, 2026
AboutOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.Show more
- Revenue$0
- EBITDA-$62M-15.6%
- Net Income-$60M-13.0%
- EPS (Diluted)-4.40-11.4%
- ROE-74.39%+98.6%
OKUR Price & Volume
OnKure Therapeutics, Inc. (OKUR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Focus Drives Capital Burn Profile
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution risk
Key Thesis Takeaways
- OnKure Therapeutics operates as a pre-commercial biotechnology firm with a binary risk profile centered on the clinical advancement of its lead asset, OKI-179.
- While the recent reverse merger with Reneo Pharmaceuticals has significantly bolstered the balance sheet to $192.1 million in cash, the company remains entirely dependent on external financing to sustain its $11.7 million quarterly R&D expenditure.
- Investors should monitor the company's ability to navigate FDA clinical trial requirements, as the current lack of revenue generation and persistent negative operating cash flows necessitate disciplined capital management to avoid future dilution.
Verdict Logic
while the $192.1 million cash position provides a sufficient runway for near-term clinical milestones, the lack of commercial revenue and the binary nature of the OKI-179 program warrant a cautious, wait-and-see approach.
OKUR Growth Metrics
OnKure Therapeutics, Inc. (OKUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM36.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.25%
Return on Capital
10 Years-77.75%
5 Years-85.58%
3 Years-116.72%
Last Year-78.41%
OKUR Recent Earnings
OnKure Therapeutics, Inc. (OKUR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.11-49.5%
$0.74
Rev
—
$166,667
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.99+13.9%
$1.15
Rev
—
$16M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.09+9.2%
$1.20
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$1.14+7.3%
$1.23
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.11vs $0.74-49.5% | —vs $166,667 |
| Q2 2026 | Mar 12, 2026 | $0.99vs $1.15+13.9% | —vs $16M |
| Q4 2025 | Nov 6, 2025 | $1.09vs $1.20+9.2% | — |
| Q3 2025 | Aug 12, 2025 | $1.14vs $1.23+7.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for OnKure Therapeutics, Inc. (OKUR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.60 | $62.9M | -1.05 | — | — | -74.39% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $29.94 | $3.48B | -34.41 | 48.29% | -188.15% | -41.54% | — | |
| $15.49 | $1.99B | 7.48 | 20.38% | 99.97% | 64.48% | — |
Compare OKUR vs Peers
OnKure Therapeutics, Inc. (OKUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OKUR SEC Filings & Documents
OnKure Therapeutics, Inc. (OKUR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OKUR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OKUR Frequently Asked Questions
OnKure Therapeutics, Inc. (OKUR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OKUR profitable?
OnKure Therapeutics, Inc. (OKUR) reported a net loss of $43.6M for fiscal year 2025.
Dividend & Returns
What is OKUR's return on equity?
OnKure Therapeutics, Inc. (OKUR) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.
What is OnKure Therapeutics, Inc.'s free cash flow?
OnKure Therapeutics, Inc. (OKUR) had negative free cash flow of $50.8M in fiscal year 2025, likely due to heavy capital investments.